Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Shapiro

Showing results (1071-1080 of 1,171) with videos related to

Pageof 118
Sort By:
Nature Cancer|March 19, 2021
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancerAnita K Mehta, Emily M Cheney, Christina A Hartl, et al.
Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Cancer Cell|June 15, 2010
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsJulian Carretero, Takeshi Shimamura, Klarisa Rikova, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Cancer Research|September 25, 2023
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor GenesYeying Huang, R Taylor Durall, Nhi M Luong, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 23, 2021
Observation unit use among patients with cancer following emergency department visits: Results of a multicenter prospective cohort from CONCERNAdam D Klotz, Jeffrey M Caterino, Danielle Durham, et al.
Influenza and Other Respiratory Viruses|January 6, 2021
Symptoms and recovery among adult outpatients with and without COVID-19 at 11 healthcare facilities-July 2020, United StatesKiva A Fisher, Samantha M Olson, Mark W Tenforde, et al.
Pageof 118

Showing results (1071-1080 of 1,171) with videos related to

Sort By:
Pageof 118
Nature Cancer|March 19, 2021
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancerAnita K Mehta, Emily M Cheney, Christina A Hartl, et al.
Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Cancer Cell|June 15, 2010
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsJulian Carretero, Takeshi Shimamura, Klarisa Rikova, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Cancer Research|September 25, 2023
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor GenesYeying Huang, R Taylor Durall, Nhi M Luong, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 23, 2021
Observation unit use among patients with cancer following emergency department visits: Results of a multicenter prospective cohort from CONCERNAdam D Klotz, Jeffrey M Caterino, Danielle Durham, et al.
Influenza and Other Respiratory Viruses|January 6, 2021
Symptoms and recovery among adult outpatients with and without COVID-19 at 11 healthcare facilities-July 2020, United StatesKiva A Fisher, Samantha M Olson, Mark W Tenforde, et al.
Pageof 118